Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accounts Payables: 2014-2024

Historic Accounts Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $2.1 million.

  • Viridian Therapeutics, Inc.\DE's Accounts Payables rose 58.77% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 58.77%. This contributed to the annual value of $2.1 million for FY2024, which is 4.29% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Accounts Payables of $2.1 million as of FY2024, which was down 4.29% from $2.2 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Accounts Payables ranged from a high of $14.2 million in FY2022 and a low of $670,000 during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $2.2 million (2023), whereas its average is $6.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 511.16% in 2022, then slumped by 84.27% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Accounts Payables stood at $670,000 in 2020, then skyrocketed by 247.61% to $2.3 million in 2021, then spiked by 511.16% to $14.2 million in 2022, then tumbled by 84.27% to $2.2 million in 2023, then decreased by 4.29% to $2.1 million in 2024.